Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVNC Revance Therapeutics Inc

休市中 12-20 15:59:59 EST

3.09

+0.02

+0.65%

盘后3.05

-0.04-1.29%

18:05 EST

最高3.09	最低3.07	成交量345.87万
今开3.07	昨收3.07	日振幅0.65%
总市值3.24亿	流通市值2.98亿	总股本1.05亿
成交额1,065万	换手率3.59%	流通股本9,644万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVNC","market":"US","secType":"STK","nameCN":"Revance Therapeutics Inc","latestPrice":3.09,"timestamp":1734728399999,"preClose":3.07,"halted":0,"volume":3458749,"hourTrading":{"tag":"盘后","latestPrice":3.05,"preClose":3.09,"latestTime":"18:05 EST","volume":173451,"amount":535907.392,"timestamp":1734735953605},"delay":0,"floatShares":96444727,"shares":104902388,"eps":-1.906672,"marketStatus":"休市中","marketStatusCode":7,"change":0.02,"latestTime":"12-20 15:59:59 EST","open":3.07,"high":3.09,"low":3.07,"amount":10650934.619832,"amplitude":0.006515,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.906672,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1391662800000,"adjPreClose":3.07,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":3.0703,"preClose":3.07,"latestTime":"09:12 EST","volume":76,"amount":232.883509,"timestamp":1734703933695},"postHourTrading":{"tag":"盘后","latestPrice":3.05,"preClose":3.09,"latestTime":"18:05 EST","volume":173451,"amount":535907.392,"timestamp":1734735953605},"volumeRatio":1.0391572282659274,"optionData":{"bulkOrders":[{"symbol":"RVNC","call":true,"expireDate":1737090000000,"strike":"3.0","timestamp":1734707531957,"price":0.20000000298023224,"volume":3000,"amount":60000,"type":"+"}]},"impliedVol":0.6545,"impliedVolPercentile":0.131},"requestUrl":"/m/hq/s/RVNC/tweets","defaultTab":"tweets","newsList":[{"id":"2490774859","title":"BUZZ--美国股票走势-华纳兄弟、Seres Therapeutics、Enterprise Bancorp","url":"https://stock-news.laohu8.com/highlight/detail?id=2490774859","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490774859?lang=zh_cn&edition=full","pubTime":"2024-12-09 23:51","pubTimestamp":1733759515,"startTime":"0","endTime":"0","summary":".N美国东部时间10:30，道琼斯工业平均指数.DJI下跌0.04%，报44,626.17点；标普500指数.SPX下跌0.28%，报6,072.92点；纳斯达克综合指数.IXIC下跌0.33%，报19,794.60点。** Interpublic Group of Companies Inc IPG.N，上涨 11.0. ** Albemarle Corp ALB.N，上涨 6.7 标普500指数.PL.INX跌幅前三位的是 ** Vistra Corp VST.N，下跌 7.0. ** OneConnect Financial Technology Co Ltd OCFT.N，上涨 17.4 纽约证券交易所.PL.N百分比跌幅前三名： ** Redwire Corp RDW.N，下跌 10.5. nL6N3NA0ET  ** Riot Platforms Inc RIOT.O:BUZZ - 在宣布发行可转换债券以购买更多比特币后下跌。nL6N3NA0FG  ** Alexandria Real Estate Equities Inc ARE.N:BUZZ - 在批准 5 亿美元股票回购计划后上涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4T3NA17S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSY","M","CMCSA","OCFT","MCRB","PTVE","NVDA","IPG","NVDS","ARE","SCCO","VST","RVNC","NVDY","ZEO","ANGO","WBD","DOW","ALB","ACLX","CHRW","TWI","NEM","EBTC","NVDX","XIN","RAD.AU","AEO","NKLA","RIO.AU","LDTC","RDW","BIOA","VSCO","RIO.UK","06638","CHTR","SG","DOUG","FCX","INDB","DDOG","BHP.AU"],"gpt_icon":1},{"id":"2490964775","title":"BUZZ-Revance Therapeutics 同意低价收购交易后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2490964775","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490964775?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:55","pubTimestamp":1733756148,"startTime":"0","endTime":"0","summary":"    12月9日 - ** 抗皱注射剂生产商Revance Therapeutics  股价下跌20.9%，至3.02美元 ** RVNC称私营护肤品公司Crown Laboratories将以每股3.10美元的价格全现金收购它  ** 该交易的总股本价值约为 3.25 亿美元** 8月份达成的最初协议是以每股6.66美元的价格收购RVNC。** 在 Revance 于 9 月收到一份指控其违反 Teoxane独家分销协议的 通知后，收购价格被降低。** 交易完成后，RVNC将成为一家私营公司** 新交易较RVNC 12月6日的收盘价折价18.9 ** 预计交易将于 2025 年第一季度完成** 截至上次收盘，股价已累计下跌 56.5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LENZ","RVNC","BK4007","BK4139","BK4588","LU0053671581.USD"],"gpt_icon":0},{"id":"2490577334","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2490577334","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490577334?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:37","pubTimestamp":1733755074,"startTime":"0","endTime":"0","summary":"     路透12月9日 - 截至格林尼治标准时间周一14:30，报道了以下竞购、兼并、收购和处置：    ** 抗皱注射剂生产商Revance Therapeutics   同意以每股3.10美元的价格被私人控股的Crown Laboratories收购，而不是之前同意的每股6.66美元，两家公司表示。** Arthur J Gallagher   表示，该公司将以价值134.5亿美元的全现金交易收购保险经纪公司AssuredPartners，以加强其在全美范围内对财产和意外事故以及员工福利的关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0477156797.USD","BK4009","BK4135","DOW","INDB","BK4548","LU0006061336.USD","LU1668664300.SGD","LU1599440770.SGD","IE00B775SV38.USD","IE00B3S45H60.SGD","SG9999014005.SGD","LU1363072403.SGD","LU0154245756.USD","BK4585","LU0321505868.SGD","SG9999014039.USD","LU1323610961.USD","LU0742537680.HKD","LU0130518102.USD","LU1791807156.HKD","OMC","APO","BK4588","IE00B19Z3B42.SGD","LU0731783048.USD","LU1201861165.SGD","IE00BVYPNW00.USD","LU1366333091.USD","IE00B42XCP33.USD","LU0321505439.SGD","BK4007","LU0106831901.USD","LU0731783394.SGD","LU1481011911.USD","IE0002270589.USD","BK4136","AJG","LU0648000940.SGD","LU1481011671.HKD","PTVE","RVNC","EBTC","IE00BGHQF631.EUR","BK4184","IE00B19Z3581.USD","LU0772969993.USD","BK4173","LU0053671581.USD","IPG"],"gpt_icon":0},{"id":"2490577544","title":"Revance Therapeutics, Inc.股价重挫20.40% 市值跌6507.13万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490577544","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490577544?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:30","pubTimestamp":1733754625,"startTime":"0","endTime":"0","summary":"北京时间2024年12月09日22时30分，Revance Therapeutics, Inc.股票出现异动，股价快速下挫20.40%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Sonnet Biotherapeutics Holdings, Inc.、Metagenomi, Inc.、Celularity Inc C/Wts 16/07/2026 涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Dermata Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为2035.00%、22.43%、18.51%，振幅较大的相关个股有Tnf Pharmaceuticals, Inc.、Unity Biotechnology, Inc.、Allogene Therapeutics, Inc.，振幅分别为108.26%、101.68%、101.37%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209223026ab6a08e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209223026ab6a08e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4007","LENZ","BK4585","LU0053671581.USD","RVNC"],"gpt_icon":0},{"id":"2490780637","title":"更新版 1-Revance 同意皇冠实验室提出的较低价格收购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=2490780637","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490780637?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:28","pubTimestamp":1733754499,"startTime":"0","endTime":"0","summary":"     路透12月9日 - 抗皱注射剂生产商Revance Therapeutics   和私人控股公司Crown Laboratories周一表示，两家公司已同意以每股3.10美元的 价格收购Revance Therapeutics   ，而不是之前商定的每股6.66美元。Revance 的股价在盘前交易中下跌了 20.4%。Revance在9月份表示，它收到了一份违反Teoxane皮肤填充剂独家经销协议的通知，因此降低了收购报价。这导致 Crown 和 Revance 延长了 8 月份首次宣布的交易完成日期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","LU0053671581.USD","RVNC","BK4585"],"gpt_icon":0},{"id":"2490727964","title":"Revance 同意皇冠实验室的低价收购要约","url":"https://stock-news.laohu8.com/highlight/detail?id=2490727964","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490727964?lang=zh_cn&edition=full","pubTime":"2024-12-09 21:42","pubTimestamp":1733751747,"startTime":"0","endTime":"0","summary":"Revance 同意皇冠实验室的低价收购要约路透12月9日 - 抗皱注射剂生产商Revance Therapeutics RVNC.O和私人控股公司Crown Laboratories周一表示，两家公司已同意以每股3.10美元的价格收购Revance Therapeutics RVNC.O，而不是之前商定的每股6.66美元。Revance股价在盘前交易中下跌了20.4%。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nL4S3NA0Z1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","LU0053671581.USD","RVNC","BK4585"],"gpt_icon":0},{"id":"2489112146","title":"Revance Therapeutics, Inc.盘中异动 大幅上涨5.10%报4.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489112146","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489112146?lang=zh_cn&edition=full","pubTime":"2024-12-05 03:11","pubTimestamp":1733339492,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日03时11分，Revance Therapeutics, Inc.股票出现波动，股价快速拉升5.10%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Exicure, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Can Fite Biopharma Ltd、Windtree Therapeutics, Inc.较为活跃，换手率分别为4381.05%、281.22%、143.40%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Nkgen Biotech Inc C/Wts 31/05/2028，振幅分别为548.98%、287.57%、64.57%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120503113298e56867&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120503113298e56867&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","LENZ","LU0053671581.USD","BK4007","RVNC","BK4139"],"gpt_icon":0},{"id":"2488594618","title":"Revance Therapeutics, Inc.盘中异动 股价大涨5.09%报3.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488594618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488594618?lang=zh_cn&edition=full","pubTime":"2024-12-03 22:32","pubTimestamp":1733236337,"startTime":"0","endTime":"0","summary":"北京时间2024年12月03日22时32分，Revance Therapeutics, Inc.股票出现异动，股价急速拉升5.09%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Janux Therapeutics, Inc.、Coherus Biosciences, Inc.、Vir Biotechnology, Inc.涨幅较大，Nls Pharmaceutics Ltd.、Purple Biotech Ltd、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为129.53%、57.73%、53.11%，振幅较大的相关个股有Coherus Biosciences, Inc.、Klotho Neurosciences, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为15.33%、12.00%、11.65%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203223218a26995c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203223218a26995c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVNC","LENZ","BK4585","BK4139","LU0053671581.USD","BK4588","BK4007"],"gpt_icon":0},{"id":"2486028980","title":"Revance Therapeutics, Inc.盘中异动 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486028980","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486028980?lang=zh_cn&edition=full","pubTime":"2024-11-26 22:36","pubTimestamp":1732631779,"startTime":"0","endTime":"0","summary":"北京时间2024年11月26日22时36分，Revance Therapeutics, Inc.股票出现波动，股价大幅拉升5.26%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Poseida Therapeutics, Inc.、Fate Therapeutics, Inc.、Cabaletta Bio, Inc.涨幅较大，Oncternal Therapeutics, Inc.、Poseida Therapeutics, Inc.、木薯科学较为活跃，换手率分别为14.60%、10.85%、9.65%，振幅较大的相关个股有Cabaletta Bio, Inc.、Fate Therapeutics, Inc.、Caribou Biosciences, Inc.，振幅分别为19.65%、16.32%、15.35%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126223619971a8a1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126223619971a8a1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4007","BK4588","LU0053671581.USD","RVNC","LENZ"],"gpt_icon":0},{"id":"2484923380","title":"Revance Therapeutics, Inc.盘中异动 早盘股价大跌5.01%报3.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484923380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484923380?lang=zh_cn&edition=full","pubTime":"2024-11-19 22:36","pubTimestamp":1732026977,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日22时36分，Revance Therapeutics, Inc.股票出现异动，股价大幅跳水5.01%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，Psyence Biomedical Ltd C/Wts 25/01/2029、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Exicure, Inc.涨幅较大，Tff Pharmaceuticals, Inc.、Hcw Biologics Inc.、Exicure, Inc.较为活跃，换手率分别为645.07%、81.68%、66.38%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Tff Pharmaceuticals, Inc.、Sab Biotherapeutics Inc C/Wts 22/10/2026 ，振幅分别为52.14%、32.55%、28.79%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922361798e43803&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922361798e43803&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0053671581.USD","BK4007","RVNC","BK4588","BK4585","LENZ"],"gpt_icon":0},{"id":"2482787738","title":"Revance Therapeutics, Inc.盘中异动 早盘股价大涨5.27%报3.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482787738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482787738?lang=zh_cn&edition=full","pubTime":"2024-11-11 22:43","pubTimestamp":1731336222,"startTime":"0","endTime":"0","summary":"北京时间2024年11月11日22时43分，Revance Therapeutics, Inc.股票出现异动，股价急速拉升5.27%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。其相关个股中，Cero Therapeutics Holdings, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Pyxis Oncology, Inc.涨幅较大，Revelation Biosciences, Inc.、Cero Therapeutics Holdings, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为432.55%、187.45%、90.64%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Revelation Biosciences, Inc.，振幅分别为76.29%、31.82%、22.93%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111224342a22ceb01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111224342a22ceb01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","BK4139","RVNC","LU0053671581.USD","BK4585","LENZ"],"gpt_icon":0},{"id":"2482626739","title":"Revance Therapeutics, Inc.2024财年第三财季实现净利润-38.12百万美元，同比增加72.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482626739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482626739?lang=zh_cn&edition=full","pubTime":"2024-11-11 00:00","pubTimestamp":1731254421,"startTime":"0","endTime":"0","summary":"11月11日，Revance Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-38.12百万美元，同比增加72.96%；其中营业收入为59.88百万美元，同比增加5.46%，每股基本收益为-0.37美元。从资产负债表来看，Revance Therapeutics, Inc.总负债6.25亿美元，其中短期债务27.36百万美元，资产负债比为0.74，流动比率为0.05。机构评级：截至2024年11月11日，当前有7家机构对Revance Therapeutics, Inc.目标价做出预测，其中目标均价为9.23美元，其中最低目标价为6.00美元，最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000030abb36203&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111000030abb36203&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVNC","LENZ"],"gpt_icon":0},{"id":"1174788842","title":"异动解读 | Revance撤回全年预期并推迟并购交易 盘中重挫逾26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174788842","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174788842?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:35","pubTimestamp":1731076501,"startTime":"0","endTime":"0","summary":"美国生物科技公司Revance Therapeutics Inc今日盘中股价大跌26.82%,收于3.56美元,引发市场广泛关注。首先,Revance宣布撤回之前提供的全年业绩指引,不再给出任何前瞻性预测。另一方面,Revance与Crown Labs的合并交易也出现延迟,双方同意将要约收购的最后期限延长至11月12日。该笔并购交易拖延较久,更令投资者对其能否最终完成产生重大疑虑,进一步打击了市场对Revance前景的信心。值得注意的是,Revance股价在过去一段时间内已累积下跌超过32%,持续的下滑走势更为今日重挫火上浇油。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVNC"],"gpt_icon":0},{"id":"2481104885","title":"Revance Therapeutics, Inc.股价重挫26.04% 市值跌1.17亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481104885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481104885?lang=zh_cn&edition=full","pubTime":"2024-11-08 22:31","pubTimestamp":1731076296,"startTime":"0","endTime":"0","summary":"北京时间2024年11月08日22时31分，Revance Therapeutics, Inc.股票出现波动，股价急速下跌26.04%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。其相关个股中，Fortrea Holdings Inc.、Poseida Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Elevai Labs, Inc.、Matinas Biopharma Holdings, Inc.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为371.72%、16.25%、13.59%，振幅较大的相关个股有Anebulo Pharmaceuticals, Inc.、Cardiff Oncology, Inc.、Sab Biotherapeutics, Inc.，振幅分别为14.96%、13.69%、11.62%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313695bdeed7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110822313695bdeed7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4007","RVNC","LU0053671581.USD","BK4585","BK4139","LENZ"],"gpt_icon":0},{"id":"1142313771","title":"异动解读 | Revance 盘前重挫逾 15%,两大负面消息引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1142313771","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142313771?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:08","pubTimestamp":1731056903,"startTime":"0","endTime":"0","summary":"美国生物科技公司 Revance Therapeutics Inc 周三盘前股价大跌 15.57%,引发市场广泛关注。这一重挫主要源于公司相继宣布两大消息,令投资者对其未来增长前景的担忧加剧。首先,Revance 撤回了之前给出的全年业绩指引,不再提供任何前瞻性预测。此举无疑加剧了投资者对 Revance 未来增长能力的疑虑。值得注意的是,Revance 股价在过去一段时间内已累积下跌超过 32%,持续的下滑走势更为此次盘前重挫火上浇油。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVNC"],"gpt_icon":0},{"id":"1179584697","title":"异动解读 | 抗皱剂公司Revance因撤回年度预测和推迟并购交易导致股价重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1179584697","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179584697?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:37","pubTimestamp":1731055042,"startTime":"0","endTime":"0","summary":"Revance Therapeutics Inc ,这家致力于开发新型抗皱注射剂的公司,周二夜盘股价大跌16.9%,收于4.80美元,主要受两大消息影响。此次预测指引的撤回使RVNC在业内地位面临挑战。另一方面,RVNC与Crown Labs的合并交易也出现延迟。双方同意将要约收购的最后期限延长至11月12日。长期拖延的并购交易令人质疑交易能否最终完成,进一步打击了投资者的信心。值得注意的是,RVNC股价在过去一段时间内已累积下跌超过32%,持续的下滑走势更加剧了市场对公司前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 抗皱剂公司Revance因撤回年度预测和推迟并购交易导致股价重挫","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVNC"],"gpt_icon":0},{"id":"2481816594","title":"BUZZ-Revance 因公司撤回年度预测、延长要约收购截止日期而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2481816594","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481816594?lang=zh_cn&edition=full","pubTime":"2024-11-08 07:29","pubTimestamp":1731022179,"startTime":"0","endTime":"0","summary":"11月7日 -  ** 抗皱注射剂生产商Revance Therapeutics RVNC.O股价盘后下跌16.9%至4.80美元  ** 公司表示，鉴于其与Crown Labs的合并 ，公司将不提供任何前瞻性指导，并撤回之前提供的任何指导。** 补充说，其交易已被推迟，尚未开始 ** 皇冠和 Revance 同意将要约收购开始的最后期限延长至 2024 年 11 月 12 日。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4S3ME347:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","LU0128526141.USD","LU1267930573.SGD","BK4585","LU1803068623.USD","LU0053671581.USD","LU1892829315.USD","LU0128525929.USD","LU0029874061.USD","LU0310800379.SGD","BK4007","CCK","RVNC","LU0708994859.HKD","BK4126","BK4588"],"gpt_icon":0},{"id":"2480688917","title":"Revance Therapeutics, Inc.盘中异动 大幅下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480688917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480688917?lang=zh_cn&edition=full","pubTime":"2024-11-01 21:32","pubTimestamp":1730467975,"startTime":"0","endTime":"0","summary":"北京时间2024年11月01日21时32分，Revance Therapeutics, Inc.股票出现异动，股价大幅跳水5.08%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Klotho Neurosciences Inc C/Wts 21/06/2029 、Theriva Biologics, Inc.涨幅较大，Theriva Biologics, Inc.、Athira Pharma, Inc.、Elevai Labs, Inc.较为活跃，换手率分别为1286.72%、111.91%、75.01%，振幅较大的相关个股有Cyclerion Therapeutics, Inc.、Mesoblast Ltd、Athira Pharma, Inc.，振幅分别为19.38%、18.08%、12.57%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213255971a3d6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101213255971a3d6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0053671581.USD","BK4007","BK4588","LENZ","RVNC","BK4585"],"gpt_icon":0},{"id":"2479343922","title":"BUZZ--美国股票走势-Monte Rosa、EyePoint Pharma、Shake Shack","url":"https://stock-news.laohu8.com/highlight/detail?id=2479343922","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479343922?lang=zh_cn&edition=full","pubTime":"2024-10-29 00:28","pubTimestamp":1730132923,"startTime":"0","endTime":"0","summary":"        *      Eikon 个股走势搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      10月28日 - 华尔街周一开盘走高，美国主要股指在经历了动荡的一周交易后有望收复部分失地，此前将有一系列大型公司发布财报，11月5日总统大选也将进入最后阶段。美东时间12:20，道琼斯工业平均指数  上涨0.68%，报42,402.47点。标普500指数  上涨0.45%，报5,834.04点；纳斯达克综合指数  上涨0.58%，报18,625.62点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ca438d53490fb5e5880a84acba8fd54e","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","DDM","ABBV","AMZN","EVOK","CCL","AZUL","GLUE","CVX",".SPX","COP","NVDA","XOM","TQQQ","2NVD.UK","SDOW","MNQmain","AAPL","3NVD.UK","MSFT","CNC","GLW","CDW","QLD","SQQQ","ADT","ON","EYPT","QID","SHAK","RVNC","GEHC","DOG","MANU","HE","PRCT",".DJI","RBLX","L","AMIX","REAL","HUT"],"gpt_icon":1},{"id":"2478489566","title":"Revance Therapeutics, Inc.股价拉升27.87% 市值涨1.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478489566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478489566?lang=zh_cn&edition=full","pubTime":"2024-10-28 21:31","pubTimestamp":1730122260,"startTime":"0","endTime":"0","summary":"北京时间2024年10月28日21时31分，Revance Therapeutics, Inc.股票出现异动，股价急速拉升27.87%。Revance Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Monte Rosa Therapeutics, Inc.、Revance Therapeutics, Inc.涨幅较大，Tc Biopharm  Plc、Viracta Therapeutics, Inc.、Immunoprecise Antibodies Ltd.较为活跃，换手率分别为540.99%、47.82%、36.02%，振幅较大的相关个股有珐博进、Precigen, Inc.、Matinas Biopharma Holdings, Inc.，振幅分别为6.49%、4.71%、4.31%。Revance Therapeutics, Inc.公司简介：Revance Therapeutics Inc 是一家专注于美容和治疗产品的生物技术公司，包括其神经调节剂产品 DaxibotulinumtoxinA for Injection。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102821310095bd74dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102821310095bd74dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","LENZ","LU0053671581.USD","BK4007","RVNC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revance.com","stockEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":-0.1868},{"period":"3month","weight":-0.4682},{"period":"6month","weight":0.1617},{"period":"1year","weight":-0.6335},{"period":"ytd","weight":-0.6485}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revance Therapeutics, Inc.于1999年8月10日成立于特拉华公司，当时名为Essentia Biosystems公司。公司是一家处于专业临床阶段的生物制药公司，专注于开发、制造和商业化用以美容和治疗的异常型肉毒杆菌毒素产品。肉毒杆菌毒素是一种良好的蛋白，目前广泛应用于美容和治疗适应症，在美国和其他国家是一个数十亿美元的市场。目前批准和商用的肉毒杆菌毒素都是注入型的。RT001, 公司的主要候选产品，是a型肉毒毒素局部配方,相对于现有注射肉毒杆菌毒素市场产品，被认为有显著的优势。公司的第二个候选产品RT002，是一种新型注射肉毒杆菌毒素类型的配方，其设计更有针对性，与其他肉毒杆菌毒素注射产品相比，更持久。这些候选产品，结合了公司的净化肉毒杆菌毒素和专有肽输送系统。公司对其两个候选产品，在全球拥有发行权利。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.017146},{"month":2,"riseRate":0.6,"avgChangeRate":0.034292},{"month":3,"riseRate":0.363636,"avgChangeRate":0.011213},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.023839},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.009304},{"month":6,"riseRate":0.636364,"avgChangeRate":0.025437},{"month":7,"riseRate":0.272727,"avgChangeRate":0.019423},{"month":8,"riseRate":0.454545,"avgChangeRate":0.053158},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.007424},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.056267},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.038099},{"month":12,"riseRate":0.545455,"avgChangeRate":0.06344}],"exchange":"NASDAQ","name":"Revance Therapeutics Inc","nameEN":"Revance Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revance Therapeutics Inc(RVNC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revance Therapeutics Inc,RVNC,Revance Therapeutics Inc股票,Revance Therapeutics Inc股票老虎,Revance Therapeutics Inc股票老虎国际,Revance Therapeutics Inc行情,Revance Therapeutics Inc股票行情,Revance Therapeutics Inc股价,Revance Therapeutics Inc股市,Revance Therapeutics Inc股票价格,Revance Therapeutics Inc股票交易,Revance Therapeutics Inc股票购买,Revance Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revance Therapeutics Inc(RVNC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revance Therapeutics Inc(RVNC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}